Sai Life Sciences (SAILIFE) | Stock Overview & Key Data
Sai Life Sciences Performance Comparison
Stock Range
Today's Range
Low: ₹855.25
High: ₹890.25
on October 1, 2025
52 Week Range
Low: ₹636.10
High: ₹943.00
on April 9, 2025
All-Time High: ₹943.00 on August 25, 2025
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR180.3B
EPS
11.67
P/E Ratio (TTM)
73.75
Forward P/E
52.85
P/B Ratio
8.42
PEG Ratio
N/A
Div. Yield
N/A
ROE
7.99%
Beta
N/A
Debt to Equity
16.56
Financial Highlights
Profitability
Gross Margin
39.22%
Operating Margin
16.76%
Profit Margin
12.77%
Returns and Earnings
Return on Assets (TTM)
5.38%
Return on Equity (TTM)
7.99%
EBITDA
INR5.4B
Net Income (TTM)
INR2.4B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR91.71
Quarterly Revenue Growth (YoY)
77.50%
Quarterly Earnings Growth (YoY)
12.12%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Sai Life Sciences SAILIFE | 180.28B Mid-cap | -0.54% | 4.98% | 13.77% | 17.23% | 17.04% | 26.08% | 26.08% | 26.08% |
| Dr. Lal PathLabs LALPATHLAB | 265.33B Large-cap | -4.11% | -3.16% | 14.23% | 32.06% | 3.79% | -9.34% | 29.77% | 54.23% |
| Syngene SYNGENE | 250.35B Large-cap | -3.23% | -1.94% | -2.51% | -13.27% | -29.16% | -28.05% | 10.41% | 11.27% |
| Metropolis METROPOLIS | 106.47B Mid-cap | -1.97% | -5.00% | 19.34% | 33.83% | -0.75% | -8.67% | 32.94% | 3.77% |
| Vijaya Diagnostic VIJAYA | 104.75B Mid-cap | -4.61% | -3.82% | 2.36% | 3.12% | -5.56% | 1.47% | 117.04% | 60.08% |
| Thyrocare THYROCARE | 64.96B Mid-cap | -4.77% | -10.95% | 17.89% | 59.18% | 24.62% | 42.83% | 65.94% | 7.48% |
Ownership & Short Interest
Insider Ownership
41.62%
Institutional Ownership
37.21%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
832K
Average 90-Day Volume
2M
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is SAILIFE's 52-week high and low?
- In the last 52 weeks, Sai Life Sciences reached a high of ₹943.00 (on N/A) and a low of ₹636.10 (on April 9, 2025).
- What is the market cap and P/E ratio for SAILIFE?
- Curious about Sai Life Sciences's size and valuation? Its market capitalization stands at 180.28B. When it comes to valuation, the P/E ratio (trailing twelve months) is 73.75, and the forward P/E (looking ahead) is 52.85.
- Does SAILIFE pay dividends? If so, what's the yield?
- As for dividends, Sai Life Sciences isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Sai Life Sciences's main competitors or similar companies to consider before investing?
When looking at Sai Life Sciences, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Dr. Lal PathLabs
LALPATHLAB265.33B Healthcare Diagnostics & Research -9.34% 29.77% Syngene
SYNGENE250.35B Healthcare Diagnostics & Research -28.05% 10.41% Metropolis
METROPOLIS106.47B Healthcare Diagnostics & Research -8.67% 32.94% Vijaya Diagnostic
VIJAYA104.75B Healthcare Diagnostics & Research 1.47% 117.04% Thyrocare
THYROCARE64.96B Healthcare Diagnostics & Research 42.83% 65.94% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Sai Life Sciences Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Sai Life Sciences's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 7.99%, the Debt to Equity ratio from the most recent quarter is 16.56, and its Gross Profit Margin stands at 39.22%.
- What is the recent revenue and earnings growth for SAILIFE?
- Looking at Sai Life Sciences's growth, its revenue over the trailing twelve months (TTM) was INR19B. Compared to the same quarter last year (YoY), quarterly revenue grew by 77.50%, and quarterly earnings saw a YoY growth of 12.12%.
- How much of SAILIFE stock is held by insiders and institutions?
- Wondering who owns Sai Life Sciences stock? Company insiders (like executives and directors) hold about 41.62% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 37.21%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.